ArticleScientific reports2026
National and subnational analysis of self-reported diabetes mellitus and health inequalities in Europe.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Diabetes mellitus (DM) has been a major public health concern with increased epidemiologic and economic burden in Europe. We aimed to estimate self-reported national and subnational DM prevalence and inequalities in individuals aged 50 years and over in 13 European countries between 2010 and 2019. Microdata were extracted from waves 4 (2010/2011), 5 (2013), 6 (2015), 7 (2017/2018) and 8 (2019) of the Survey of Health, Ageing and Retirement in Europe (SHARE) database. The analysis was conducted at both national and subnational levels, comprising 13 European countries. Health inequalities were assessed using the gini coefficient (GC) and concentration index (CI). Socioeconomic risk factors were included in the inequality analysis (urbanization, income, and educational level) in addition to multilevel regression model. The prevalence of DM decreased from 11% in wave 4 to 10.6% in wave 8, with the lowest recorded in Switzerland at 5.9% in wave 5 and the highest observed in Czechia at 16.7% in wave 8. DM prevalence varied widely subnationally, ranging from 2.1% in wave 8 Zentralschweiz (Switzerland) to 28.5% in wave 8 in Střední Čechy in Czechia. The GC demonstrated an increase from 21.9% (95% CI 17.0, 24.5) in wave 4 to 22.5% (95% CI 19.4,25.2) in wave 8, with Switzerland exhibiting the highest coefficient in wave 8 [30.1% (95% CI 7.9, 41.7)]. The CIs for income and educational level at national level were consistently low and mostly negative. The education and income CI ranged from [- 0.0182 (95% CI - 0.0242, - 0.0122) to - 0.0010 (95% CI - 0.0021, - 0.0001)] and [- 0.0278 (95% CI - 0.0411, -0.0166) to - 0.0018 (95% CI - 0.0032, - 0.0005)] across waves 4 and 8, respectively. The CI for urbanization displayed both negative and positive values, but most were not statistically significant (p > 0.05). Inequalities exist in the self-reported prevalence of DM both nationally and subnationally, with elevated rates observed among individuals with lower educational and income levels. Addressing these significant health inequalities calls for the development of prevention programs and policies by the European countries and subnational regions, specifically tailored to prioritize and support vulnerable groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.